Premium
Red blood cell in vitro quality and function is maintained after S ‐303 pathogen inactivation treatment
Author(s) -
Winter Kelly M.,
Johnson Lacey,
Kwok Matthew,
Vidovic Diana,
Hyland Ryan A.,
Mufti Nina,
Erickson Anna,
Marks Denese C.
Publication year - 2014
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.12545
Subject(s) - hemolysis , glycophorin , in vitro , flow cytometry , andrology , red blood cell , hemoglobin , pathogen , chemistry , biology , immunology , biochemistry , medicine , antigen
Background Over the past decade there has been a growth in the development of pathogen reduction technologies to protect the blood supply from emerging pathogens. This development has proven to be difficult for red blood cells ( RBC s). However the S ‐303 system has been shown to effectively inactivate a broad spectrum of pathogens, while maintaining RBC quality. Study Design and Methods A paired three‐arm study was performed to compare the in vitro quality of S ‐303–treated RBC s with RBC s stored at room temperature ( RT ) for the duration of the treatment (18‐20 hr) and control RBC s stored at 2 to 6° C . Products were sampled weekly over 42 days of storage (n = 10) and tested using an array of in vitro assays to measure quality, metabolism, and functional variables. Results During S ‐303 treatment there was a slight loss of RBC s and hemoglobin ( Hb < 5 g). Hemolysis, glucose consumption, and potassium release were similar in all groups during the 42 days of storage. S ‐303–treated RBC s had a significantly lower lactate concentration and pH compared to the paired controls. The S ‐303–treated RBC s had significantly higher adenosine triphosphate than the RT and control RBC s. There was a significant loss of 2,3‐diphosphoglycerate in the S ‐303–treated products, which was also observed in the RT RBC s. Flow cytometry analysis demonstrated similar RBC size, morphology, expression of CD 47, and glycophorin A in all groups. Conclusion RBC s treated with S ‐303 for pathogen reduction had similar in vitro properties to the paired controls and were within transfusion guidelines.